BridgeBio Pharma, Inc. Equity Securities, FV-NI, Unrealized Loss
BridgeBio Pharma, Inc. (BBIO) reported Equity Securities, FV-NI, Unrealized Loss of $11.95 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2023-02-23
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2022-06-30 was $10.22M, a 815.04% increase year-over-year.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2022-03-31 was $11.62M.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2021-06-30 was $1.12M.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2022 was $11.95M, a 70.72% decline from fiscal 2021.
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized loss for fiscal 2021 was $40.83M.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|
| 2022-12-31 | $11.95M 10-K · filed 2023-02-23 | ||
| 2022-06-30 | $10.22M 10-Q · filed 2022-08-04 | $21.84M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $11.62M 10-Q · filed 2022-05-05 | ||
| 2021-12-31 | $40.83M 10-K · filed 2023-02-23 | ||
| 2021-06-30 | $1.12M 10-Q · filed 2022-08-04 | $1.12M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |